Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.68 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438759 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL17694454 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL21738174 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL13701713 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL5439873 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL19478069 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL24376776 | 1.00 | EPHX1 (0.68) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL6840451 | 0.98 | EPHX1 (0.64) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| Sulfuric Acid SCHEMBL27634420 | 0.94 | EPHX1 (0.61) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| Sulfuric Acid SCHEMBL27634416 | 0.94 | EPHX1 (0.61) | EPHX1CASP2ZDHHC20ZDHHC2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | EPHX1 1880/4885CASP2 2856/4885ZDHHC20 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.